Twist Bioscience Shares Gain on Antibody Evaluating Service

Dow Jones10-29

Shares of Twist Bioscience rose after the biotechnology company announced a service that can produce and quickly evaluate antibodies for artificial-intelligence drug discovery research.

Shares were up 10% at $175.81 as of midday Wednesday. The stock has more than quintupled in value this year.

The company said the service, with a turnaround time as short as five days, would help bridge the gap between early antibody binding data and drug development.

"Twist Express Screening Antibodies bring speed and scalability to early-stage characterization, enabling researchers to move broader candidate sets from sequence to data, iterate faster and focus downstream development resources on the antibodies with the greatest potential," Chief Executive Officer Emily Leproust said.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment